Navigation Links
Genencor Appoints New Executive Vice President - Technical Enzymes
Date:10/1/2007

Glenn E. Nedwin, Ph.D., MBA to Join Genencor's Senior Management Team

ROCHESTER, N.Y., Oct. 1 /PRNewswire/ -- Genencor, a division of Danisco A/S, today announced that Dr. Glenn E. Nedwin will join the Division as Executive Vice President - Technical Enzymes, effective Oct. 1, 2007. As a member of the Genencor Senior Management Team, Dr. Nedwin will head the division's activities in Grain Processing (which includes current fuel ethanol business), Textiles, Specialties & Market Development. He will report directly to Genencor's CEO Tjerk de Ruiter.

Dr. Nedwin comes to Genencor from being Interim President and Chief Science Officer at Dyadic International, Inc., a biotech company active in the bioenergy and industrial enzymes fields. Prior to joining Dyadic, Dr. Nedwin was President of Novozymes, Inc., where he established the company's US R&D headquarters for Novozymes A/S, as well being active in business development. In addition to his 14+ years with Novozymes, his career has included key positions with XOMA Corporation, Ideon Corporation, Molecular Therapeutics, Inc., and Genentech, Inc.

Dr. Nedwin's appointment continues to enhance Genencor's world-class, organization and Management Team. "He brings both established leadership and international business experience with him to the division," said Tjerk de Ruiter, CEO of Genencor. "Our goal is to be the growth engine of Industrial Biotechnology and Dr. Nedwin's experience and vision will certainly help us get there."

In addition to de Ruiter and Nedwin, the Genencor Senior Management Team includes James Laughton, Executive Vice President - Food & Feed; Philippe Lavielle, Executive Vice President - Business Development; Michael Arbige, PhD., Executive Vice President - Technology; Carole Cobb, Senior Vice President - Global Supply; Jim Sjoerdsma, Senior Vice President - Human Resources; and Andrew Ashworth, Vice President - Finance.

About Genencor

Genencor, a division of Danisco A/S, is a leader in the industrial biotechnology sector. In more than 40 countries, Genencor's 1,500 employees develop and market innovative enzymes and biobased solutions to improve the performance and reduce the environmental impact of a wide variety of industries, from laundry detergents to transportation fuels. Genencor also develops and produces enzymes for the food, beverage and animal nutrition industries, which are sold under the Danisco brand. In partnership with our customers, technology leaders and other stakeholders, Genencor's cutting-edge biotech platform provides competitive and sustainable solutions to the world, positioning Genencor as one of the leaders in the emerging biobased economy.


'/>"/>
SOURCE Genencor
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017  Ascendis Pharma ... its innovative TransCon technology to address significant unmet ... results for the full year ended December 31, ... year for our company as we broadened our ... leading, integrated rare disease company with an initial ...
(Date:3/22/2017)... 22, 2017   iSpecimen ®, the ... Doctors Pathology Service (DPS), a full-service anatomic pathology ... the United States , has joined a program ... Network (DHIN) to make human biospecimens and associated ... novel program, announced in 2015 as a collaboration between ...
(Date:3/22/2017)... CAMBRIDGE, Mass. , March 22, 2017   ... of next-generation cancer therapeutics designed to target cancer stemness ... Patricia S. Andrews as Chief Executive Officer, ... will succeed Chiang J. Li , M.D., FACP, ... company ten years ago. Under his leadership, Boston Biomedical ...
(Date:3/22/2017)... ... March 21, 2017 , ... Proper glycosylation is critical ... desired increase and/or decrease in antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity, there is ... antibodies. , To meet this demand, the team at SCIEX has developed ...
Breaking Biology Technology:
(Date:2/28/2017)... February 28, 2017 News solutions for biometrics, ... ... from 14 to 16 March, Materna will present its ... how seamless travel is a real benefit for passengers. To ... to their passenger touch point solutions to take passengers through the ...
(Date:2/26/2017)...  Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring, announces the appointment of ... "Too often, too many offenders return to jail ... trying to tackle this ongoing problem and improve ... members. While significant steps are underway, Securus continues to ...
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017 /PRNewswire/ ... of Companies (Avamere Health Services, Infinity Rehab, Signature Hospice, ... study that will apply the power of IBM cognitive ... and health centers. By analyzing data streaming from sensors ... into physical and environmental conditions, and obtain deeper learnings ...
Breaking Biology News(10 mins):